First Comprehensive Amyloid Imaging Solution1
When evaluating for Alzheimer’s disease and other causes of cognitive decline
Quantitative Accuracy with Biograph mCT
Because some amyloid tracer is naturally retained in the normal brain, it is important to appropriately differentiate between white matter uptake and gray matter beta-amyloid plaque deposits
While amyloid tracer uptake within the brain’s white matter is, in most cases, considered normal, uptake in the gray matter may indicate abnormal activity.10 Because gray and white matter are interlaced in such a compact way, distinguishing the two can be challenging. Once localized, quantifying the presence of amyloid plaques may be useful in looking at amyloid-PET images.
Traditional scanners in use today often lack the fine volumetric resolution and high-contrast ratio required to precisely differentiate between gray and white matter. Inherent scanner drift as well as inaccurate attenuation correction impact the accuracy of acquired quantitative data. In addition, conventional interpretation software does not offer automatic, validated quantification and leaves the reader to rely solely on qualitative interpretation.
With the new Biograph™ mCT from Siemens, physicians can attain the highest image quality6 and quantifiable results that are accurate. With its OptisoHD Detection System, UltraHD•PET and acquisition matrix of 400 x 400, Biograph mCT enables physicians to visualize different brain matter with the industry’s finest volumetric resolution12 of 87mm3 and four times improvement in contrast (signal to noise). With its unique combination of daily calibration and precise anatomical and functional co-registration, Biograph mCT can make a quantifiable improvement in confidence in dementia evaluation.
syngo®.PET Amyloid Plaque1 proprietary quantification software takes a patient’s PET amyloid exam and automatically registers it against a reference model of a PET amyloid brain. syngo.PET Amyloid Plaque enables physicians to calculate uptake ratios. Combined with visual assessment, these capabilities may give physicians added information about amyloid-PET images.
1 syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
6 2011 PET Image Quality Survey conducted in the U.S. and Europe as a custom study by IMV, a neutral third party market research company.
10 Adam S. Fleisher et al: “Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease”, Archives of Neurology, July 12, 2011
11 Camus et al EJNM (2012) 39:621-631; Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment; Qualitative visual assessment of the PET scan showed a sensitivity of 84.6%; however, the quantitative assessment of the global cortex SUVr showed a sensitivity of 92.3%.
12 2011 PET Image Quality Survey conducted in the U.S. and Europe as a custom study by IMV, a neutral third party market research company.
13 J.-M. Peyrat, A. Joshi, M. Mintun, J. Declerck: “An Automatic Method for the Quantification of Uptake with Florbetapir Imaging”, SNM Publication No.: 210, Reference #: 1311229, http://www.snm.org/index.cfm?PageID=11533